In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Growth

Set Alert for Growth

Formation Secures Huge Series D For AI Platform Growth

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Artificial Intelligence Deals

BIO Roundup: Deal-Making Tips And Tricks

Key insights from the recent the BIO International Convention in San Diego, US.

Deals C-Suite Speaks

Women’s Health Innovation: What Are We Waiting For?

An investigator, an investor and an inventor walk into the New York Stock Exchange, and it’s no joke. Women’s health is a fruitful investment with a clear path to financial return. 

Women's Health Clinical Trials

Entering Estonia: To Build Bigger Castles, You Need A Better Sandbox

Estonia is hoping to  create a brighter future by attracting leading startups to its borders, a process that will bring tax revenues, jobs and infrastructure.

Estonia StartUps and SMEs

BioBytes: AI-Related Deals In Q1 2024

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.   

Artificial Intelligence Deals

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

Business Strategies Commercial

With A Transformational Year Underway, Insmed Ramps Up

With a reliable source of revenue in Arikayce and two key pulmonary late-stage trials reading out, Insmed aims to keep its commercial momentum going.

Clinical Trials Commercial

Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy

Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.

C-Suite Speaks Business Strategies

Sofinnova And J&J Offer Tips For Startups Seeking Financial Backing

Last year saw a drop in series A rounds. To increase the chances of fundraising success, new companies should engage earlier and align with potential financial backers. 

StartUps and SMEs Financing

Key Considerations When Acquiring A Cell And Gene Biotech

Stakeholders looking to gain deeper insights into potential cell and gene therapy candidates and optimize R&D strategies can employ several strategies to inform portfolio management decisions.

Growth Gene Therapy

Alys Is An Asset Play Wanting Big Pharma Attention

Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.

C-Suite Speaks Commercial Strategies

Genmab's Growth Strategy: Embracing A ‘Super Rational, Data-Driven' Mindset

The “Genmab sauce” will be crucial as the Danish biotech loads up on late-stage assets, grows its capabilities and expands into immunology and inflammation. 

Growth Business Strategies

Medtech’s Leading Revenue Earners In 2023: Johnson & Johnson Tops $30bn

Abbott’s weaker rapid diagnostic sales see the erstwhile industry leader slip down the global 2023 medtech rankings, while Johnson & Johnson passes it on the way up on the back of strong external and internal growth.

Sales & Earnings Medical Device

Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Growth Financing

The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Deals M & A

Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

Companies Deals
See All
UsernamePublicRestriction

Register